Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Адъювантная терапия в лечении гастроинтестинальных стромальных опухолей
Адъювантная терапия в лечении гастроинтестинальных стромальных опухолей
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Полный текст
Список литературы
1. Kingham T, DeMatteo R. Multidisciplinary Treatment of Gastrointestinal Stromal Tumors. Surg Clin N Am 2009; 89: 217–33.
2. De Matteo R, Ballman K, Antonescu C et al. Adjuvant imatinib mesylate after resection of localized, primary gastrointestinal stromal tumour: a randomized, double-blind, placebo-controlled trial. www.thelancet.com 2009; 373: 1097–104.
3. Gronchi A, Fiore M, Miselli F et al. Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in advanced/metastatic GIST. Ann Surg 2007; 245: 341–6.
4. Rutlowski P, Nowecki Z, Nyckowski P et al. Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate. J Surg Oncol 2006; 93: 304–11.
5. Fletcher C, Berman J, Corless C et al. Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol 2002; 33: 459–65.
6.http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=53&...
7. SSG XVIII/AIO. www.ClinicalTrials.gov:identifier: NCT00116935
8. EORTC62024.www.ClinicalTrials.gov:identifier:NCT00103168
8. Eisenberg B, Harris J, Blanke C et al. Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN:665. J Surg Oncol 2009; 99: 42–7.
9. NCCN Practice Guidelines in Oncology. 2009; 2.
10. Casali P, Jost J, Reichardt P et al. Gastrointestinal stromal tumours: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009; 20 (Suppl. 4): iv64–7.
11. Heikki Joensuu. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol 2008; 39: 1411–9.
12. Raut C, DeMatteo R. Prognostic Factors for Primary Gist: Prime Time for Personalized Therapy. Ann Surg Oncol 2008; 15 (1): 4–6.
2. De Matteo R, Ballman K, Antonescu C et al. Adjuvant imatinib mesylate after resection of localized, primary gastrointestinal stromal tumour: a randomized, double-blind, placebo-controlled trial. www.thelancet.com 2009; 373: 1097–104.
3. Gronchi A, Fiore M, Miselli F et al. Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in advanced/metastatic GIST. Ann Surg 2007; 245: 341–6.
4. Rutlowski P, Nowecki Z, Nyckowski P et al. Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate. J Surg Oncol 2006; 93: 304–11.
5. Fletcher C, Berman J, Corless C et al. Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol 2002; 33: 459–65.
6.http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=53&...
7. SSG XVIII/AIO. www.ClinicalTrials.gov:identifier: NCT00116935
8. EORTC62024.www.ClinicalTrials.gov:identifier:NCT00103168
8. Eisenberg B, Harris J, Blanke C et al. Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN:665. J Surg Oncol 2009; 99: 42–7.
9. NCCN Practice Guidelines in Oncology. 2009; 2.
10. Casali P, Jost J, Reichardt P et al. Gastrointestinal stromal tumours: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009; 20 (Suppl. 4): iv64–7.
11. Heikki Joensuu. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol 2008; 39: 1411–9.
12. Raut C, DeMatteo R. Prognostic Factors for Primary Gist: Prime Time for Personalized Therapy. Ann Surg Oncol 2008; 15 (1): 4–6.
Авторы
М.П.Никулин, И.С.Стилиди
ГУ РОНЦ РАМН им. Н.Н.Блохина, Москва
ГУ РОНЦ РАМН им. Н.Н.Блохина, Москва
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.